drugset / Trial / NCT02170038

Clinical Study Investigating the Conversion of the Contraceptive Compound Norethisterone Within the Body Towards the Contraceptive Compound Ethinylestradiol

NCT02170038

Phase 1 Completed 16 enrolled Bayer
Non-randomizedCrossoverOpen-labelBasic science

Summary

The clinical phase I study aims at investigating the conversion of the contraceptive compound norethisterone within the body towards the contraceptive compound ethinylestradiol. Therefore concentrations of ethinylestradiol will be measured from blood samples after administration of a single intramuscular dose of norethisterone. In a comparison arm concentrations of ethinylestradiol will be measured from blood samples after administration of a pill containing ethinylestradiol itself.

Timeline

Start
2014-06
Primary completion
2014-12
Completion
2015-03

Drugs

EvaluationDrugModalityDoseRoute
Subject ethinyl estradiol Small molecule 0.03 mg Oral
Subject norethisterone enantate Unknown 200 mg Intramuscular
Background Levonorgestrel Small molecule 0.15 mg Oral

Indications

No indication recorded.